{"analyses":[{"ciLowerLimit":"0.557","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.533","groupDescription":"Anetumab ravtansine versus vinorelbine","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.378916","paramType":"Hazard Ratio (HR)","paramValue":"0.924","statisticalComment":"one-sided log-rank test stratified by time to progression (TTP) on first line treatment","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"value cannot be estimated due to censored data","groupId":"OG000","lowerLimit":"127","upperLimit":"NA","value":"210"},{"comment":"value cannot be estimated due to censored data","groupId":"OG001","lowerLimit":"85","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"Time to worsening of pain (TTWP) was defined in patients evaluable for assessing worsening of pain, as time from randomization until the first worsening of pain. Patients who died, were lost to follow-up, or ended (MD Anderson Symptom Inventory-Malignant Pleural Mesothelioma) MDASI-MPM assessments without confirmed worsening of pain were censored at the date of their last MDASI-MPM assessment with a non-missing pain score.","dispersionType":"95% Confidence Interval","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"MEDIAN","populationDescription":"The secondary efficacy analysis was performed in the ITT (Intent-to-treat) analysis set.","reportingStatus":"POSTED","timeFrame":"up to approx. 30 months (data cut-off: 31-May-2017)","title":"Time to Worsening of Pain","type":"SECONDARY","unitOfMeasure":"days"}